The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
A tuberculosis vaccine developed 100 years ago also makes vaccinated persons less susceptible to other infections. While this effect has been recognized for a long time, it is not known what causes it.
As the world grapples with the coronavirus disease (COVID-19) pandemic, scientists race to develop an effective vaccine to protect against the deadly SARS-CoV-2 virus. While potential vaccines are still being developed and tested, researchers propose that existing vaccines could give the immune system a temporary boost to ward off infection.
Professor David Levine from the University of California, Berkeley, says a study of people in Spain and Italy has provided a “shred of evidence” that the BCG vaccination may protect against coronavirus disease 2019 (COVID-19).
An A$10 million grant from the Bill & Melinda Gates Foundation will allow the Murdoch Children's Research Institute's clinical trial of the BCG vaccine against COVID-19 to extend to 10,000 healthcare workers across Australia, Spain and The Netherlands.
A new paper published on the preprint server medRxiv in April 2020 challenges the hypothesis that BCG vaccination confers some degree of protection against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the pneumonic illness COVID-19.
The association between BCG (Bacillus Calmette-Guérin) vaccination and its purported beneficial effect on COVID-19 transmission/mortality rates was challenged in an expert appraisal of Diamond Princess cruise ship data. At the same time, cross-national differences previously reported were shown to be flawed, reports a new medRxiv study.
From the plagues of medieval Europe to the influenza pandemic of 1918, the specter of the next public health disaster has gripped the minds of scientists, captivated the imaginations of writers and vexed conspiracy theorists.
All over the world, except in China, the place where it all began, the COVID-19 pandemic is making its relentless way through the population. So far, it has caused nearly 34,000 deaths – and the situation in the US is still worsening with over 142,000 cases and 2,489 deaths. In Australia, the number of cases has climbed to 4,093, with 16 fatalities.
Professor Kathryn North AC, Director of the Murdoch Children's Research Institute in Melbourne, Australia, has announced its infectious disease researchers are preparing to roll-out a multi-center randomized controlled clinical trial of the BCG vaccine against COVID-19.
The coronavirus disease (COVID-19) had taken a toll on the world, affecting 168 countries and more than 417,000 people. So far, more than 18,600 people have died due to complications of the disease. Scientists across the globe race to develop the first vaccine against the novel coronavirus.
Each year, more than 100 million newborns around the world receive vaccinations against Mycobacterium tuberculosis, or TB, which infects about one-quarter of the world's population.
A new primate study published in the journal Nature in January 2020, reports that the almost century-old BCG vaccine against tuberculosis, may be used differently to achieve better protection against lung tuberculosis. While more work remains to be carried out before the findings can be accepted as the basis for clinical practice, they are extremely promising in the fight against this killer.
Researchers have found that the BCG vaccine is more efficacious in the prevention of TB when administered intravenously.
Worldwide, more people die from tuberculosis than any other infectious disease, even though the vast majority were vaccinated.
A new study published in the journal Scientific Reports says that for the first time a vaccine has been created against bovine tuberculosis that can be given without affecting the ability to diagnose tuberculosis later using the PPD skin test.
Seattle Children's Research Institute is one of three recipients of $30 million in first-year-funding provided by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to establish centers for immunology research to accelerate progress in tuberculosis vaccine development.
A team of researchers in the Department of Microbiology, Immunology and Pathology at Colorado State University aim to advance what is known about the complex immune response necessary to prevent tuberculosis disease.
The San Antonio Medical Foundation has awarded Texas Biomedical Research Institute Professor Jordi B. Torrelles, Ph.D., with a $173,000 grant to study a modified Mycobacterium bovis Bacillus Calmette et Guérin (BCG) vaccine shown to have promise for treating bladder cancer.
A new study published on October 29, 2019, in the New England Journal of Medicine, reports a new vaccine which could change the face of tuberculosis prevention. The disease kills 1.5 million people worldwide each year.